Table 3.
Referral at Baseline | Age | HPV Group n=11,339 | Cytology Group n=17,013 | OR for HPV versus Cytology Group | |||||
---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | ||||||||
(Crude) | (Adjusted*) | ||||||||
n | (%) | n | (%) | OR | (95% CI) | OR | (95% CI) | ||
New screen due to unsatisfactory test | All | 8 | (0.1) | 117 | (0.7) | 0.10 | (0.05–0.21) | 0.11 | (0.05–0.22) |
30–39 | 3 | (0.1) | 47 | (0.8) | 0.10 | (0.03–0.31) | 0.10 | (0.03–0.33) | |
40–49 | 3 | (0.1) | 40 | (0.6) | 0.11 | (0.03–0.35) | 0.11 | (0.04–0.36) | |
50–59 | 2 | (0.1) | 30 | (0.7) | 0.10 | (0.03–0.43) | 0.11 | (0.03–0.44) | |
Colposcopy | All | 436 | (3.8) | 362 | (2.1) | 1.84 | (1.60–2.12) | 1.88 | (1.63–2.17) |
30–39 | 199 | (5.3) | 182 | (3.2) | 1.69 | (1.37–2.07) | 1.73 | (1.41–2.13) | |
40–49 | 162 | (3.4) | 128 | (1.8) | 1.88 | (1.49–2.38) | 1.94 | (1.53–2.46) | |
50–59 | 75 | (2.7) | 52 | (1.2) | 2.27 | (1.59–3.25) | 2.22 | (1.55–3.17) | |
Repeat screening in 12 months | All | 566 | (5.0) | 30 | (0.2) | 29.73 | (20.58–42.96) | 29.85 | (20.65–43.14) |
30–39 | 236 | (6.3) | 12 | (0.2) | 31.59 | (17.66–56.49) | 31.44 | (17.56–56.28) | |
40–49 | 227 | (4.7) | 13 | (0.2) | 26.79 | (15.30–46.91) | 27.11 | (15.48–47.48) | |
50–59 | 103 | (3.7) | 5 | (0.1) | 33.12 | (13.48–81.34) | 32.78 | (13.33–80.63) | |
Back to routine screening | All | 10,329 | (91.1) | 16,504 | (97.0) | 0.32 | (0.28–0.35) | 0.31 | (0.27–0.34) |
30–39 | 3332 | (88.4) | 5449 | (95.8) | 0.34 | (0.29–0.40) | 0.32 | (0.28–0.38) | |
40–49 | 4415 | (91.8) | 6860 | (97.4) | 0.30 | (0.25–0.36) | 0.29 | (0.24–0.35) | |
50–59 | 2582 | (93.5) | 4195 | (98.0) | 0.30 | (0.23–0.39) | 0.30 | (0.23–0.39) |
Notes: *Adjusted for age, educational level, country of origin and employment status; 317 women with missing values of adjustment variables excluded from models.
Abbreviations: CI, confidence interval; HPV, human papillomavirus; OR, odds ratio, PPV, positive predictive value.